Business
BioAlberta’s CEO reflects on regulatory hurdles, investor gaps, and the leadership needed to turn scientific breakthroughs into commercial success.
Hi, what are you looking for?
BioAlberta’s CEO reflects on regulatory hurdles, investor gaps, and the leadership needed to turn scientific breakthroughs into commercial success.
Nucleate Canada’s upcoming Forum offers the first national look at a grassroots model for biotech commercialization.
The sector has grown from its early days of molecule discoveries into an ecosystem that includes biotech, medical devices, digital health, and AI.
It may look like an innocent green plant, but its name evokes something far closer to a robot or interstellar rocket. Neo Px is...
At the core of the discussion, panel participants will cover topics such as gene editing and other tools that are ushering in a new...
Pay attention to this tech, because it really is the future.
Joublin's strategies in biotech communications have always been personal, passionate, and profoundly effective, which helped him stand out in this industry.
Dozens of scientists, experts and campaigners called for a ban on the release of genetically-edited organisms into the wild.
Their biochemical machinery is close enough to human to produce proteins with an acceptable “finger print” in the form of post-translational modifications.
Wuxi Biologics suspended trading in Hong Kong on Tuesday following a record slump in its share price.